Work

Lessons Learned: Transfer of the High‐Definition Circulating Tumor Cell Assay Platform to Development as a Commercialized Clinical Assay Platform

Year: 2017

Type: review

Abstract: Planning and transfer of a new technology platform developed in an academic setting to a start-up company for medical diagnostic product development may appear daunting and costly in terms of complexity, time, and resources. In this review we outline the key steps taken and lessons learned when a technology platform developed in an academic setting was transferred to a start-up company for medical diagnostic product development in the interest of elucidating development toolkits for academic groups and small start-up companies starting on the path to commercialization and regulatory approval.

Source: Clinical Pharmacology & Therapeutics

DOI: 10.1002/cpt.645

Authors: P Kuhn, SM Keating, GT Baxter, K Thomas, A Kolatkar, CC Sigman

Institutions: Scripps Research Institute, CCS Associates (United States)

Language: English

Topic: Technology Assessment and Management

Subfield: Safety, Risk, Reliability and Quality

Field: Engineering

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute